摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-(4-吗啉)-1H-嘌呤 | 2846-96-0

中文名称
6-(4-吗啉)-1H-嘌呤
中文别名
4-(1H-嘌呤-6-基)吗啉
英文名称
6-morpholino-7(9)H-purine
英文别名
6-Morpholino-7(9)H-purin;6-morpholinopurine;6-Morpholin-4-Yl-9h-Purine;4-(7H-purin-6-yl)morpholine
6-(4-吗啉)-1H-嘌呤化学式
CAS
2846-96-0
化学式
C9H11N5O
mdl
MFCD00496816
分子量
205.219
InChiKey
MEOMXKNIFWDDGZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    300-301 °C
  • 沸点:
    340.4±52.0 °C(Predicted)
  • 密度:
    1.60±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.444
  • 拓扑面积:
    66.9
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:3469c867f4a384cd445c5ea7f684336c
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-(4-吗啉)-1H-嘌呤sodium acetate 作用下, 以 溶剂黄146 为溶剂, 反应 3.0h, 以85%的产率得到4-(8-bromo-9H-purin-6-yl)morpholine
    参考文献:
    名称:
    闭环易位合成稠合二氢吡啶并[ e ]嘌呤
    摘要:
    8,9-二烯丙基尿烷或9-丁烯基-8-乙烯基嘌呤与Grubbs第二代催化剂的闭环易位(RCM)分别产生了稠合的6,9-或8,9-二氢吡啶并[ e ]嘌呤。在9-烯基化之后,由8-溴嘌呤制备8,9-二烯基嘌呤,随后在Pd(PPh 3)4或Pd(PPh 3)2 Cl 2的存在下,在C-8将Stille偶联与烯基锡烷。
    DOI:
    10.1016/j.tetlet.2010.10.008
  • 作为产物:
    描述:
    参考文献:
    名称:
    Purines. VIII. The Aminolysis of Certain Chlorosubstituted Purines1
    摘要:
    DOI:
    10.1021/ja01523a075
点击查看最新优质反应信息

文献信息

  • MORPHOLINOPURINE DERIVATIVES
    申请人:Nakayama Kiyoshi
    公开号:US20100130492A1
    公开(公告)日:2010-05-27
    There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity: wherein R 1 , R 2 , R 3 , R 4 , R a , R b , R c , and X each have the same meaning as defined in the specification.
    提供了一种新型化合物,它抑制磷脂酰肌醇3-激酶(PI3K)和/或哺乳动物雷帕霉素靶蛋白(mTOR),并表现出抗肿瘤活性。本发明提供了一种由以下式(1)表示的化合物,具有各种取代基,可抑制PI3K和/或mTOR,并表现出抗肿瘤活性: 其中R1、R2、R3、R4、Ra、Rb、Rc和X的含义与规范中定义的含义相同。
  • An efficient synthesis of substituted cytosines and purines under focused microwave irradiation
    作者:Ling-Kuen Huang、Yen-Chih Cherng、Yann-Ru Cheng、Jing-Pei Jang、Yi-Ling Chao、Yie-Jia Cherng
    DOI:10.1016/j.tet.2007.02.124
    日期:2007.6
    A rapid nucleophilic displacement reaction of 6-chloropurine, 2-amino-6-chloropurine and 5-bromocytosine with various nucleophiles under focused microwave irradiation is described. Using this method, the desired products were obtained with the yields up to 99% in a short reaction time.
    描述了在聚焦微波辐射下6-氯嘌呤,2-氨基-6-氯嘌呤和5-溴胞嘧啶与各种亲核试剂的快速亲核取代反应。使用这种方法,可以在较短的反应时间内获得高达99%的收率的所需产物。
  • [EN] PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PURINE UTILES COMME INHIBITEURS DE PI3 KINASE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2009053716A1
    公开(公告)日:2009-04-30
    This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arisi from abnormal cell growth, function or behaviour associated with PI3 kinase such as cance immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    这项发明提供了一种化合物,其为式(Ia)或(Ib)的嘌呤类化合物:及其药学上可接受的盐,这些化合物是PI3K的抑制剂,并且对p110δ同工型具有选择性,p110δ是Ia类PI3激酶,优于其他Ia类PI3激酶和Ib类激酶。这些化合物可用于治疗由于与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和紊乱,如癌症、免疫紊乱、心血管疾病、病毒感染、炎症、代谢/内分泌功能紊乱和神经系统疾病。
  • Enantioselective Aluminum‐Free Alkene Hydroarylations through C−H Activation by a Chiral Nickel/JoSPOphos Manifold
    作者:Joachim Loup、Valentin Müller、Debasish Ghorai、Lutz Ackermann
    DOI:10.1002/anie.201813191
    日期:2019.2.4
    Highly enantioselective nickel‐catalyzed alkene endo‐hydroarylations were accomplished with full selectivity by organometallic C−H activation. The asymmetric assembly of chiral six‐membered scaffolds proved viable in the absence of pyrophoric organoaluminum reagents within an unprecedented nickel/JoSPOphos manifold.
    高度对映选择性的镍催化的烯烃内氢芳基化反应是通过有机金属CH活化完全选择性地完成的。在空前的镍/ JoSPOphos歧管中不存在自燃有机铝试剂的情况下,手性六元支架的不对称组装被证明是可行的。
  • Synthesis of Chiral Cyclopropyl Carbocyclic Purine Nucleosides<i>via</i>Asymmetric Intramolecular Cyclopropanations Catalyzed by a Chiral Ruthenium(II) Complex
    作者:Ke-Xin Huang、Ming-Sheng Xie、Guo-Feng Zhao、Gui-Rong Qu、Hai-Ming Guo
    DOI:10.1002/adsc.201600377
    日期:2016.11.17
    The synthesis of chiral cyclopropyl carbocyclic purine nucleoside analogues via the highly enantioselective intramolecular cyclopropanation reactions has been reported. With a chiral ruthenium(II)‐phenyloxazoline complex as the catalyst, cyclopropyl carbocyclic purine nucleoside analogues containing three contiguous stereocenters were obtained with up to 99% yield and 99% ee. Furthermore, a chiral
    已经报道了通过高度对映选择性分子内环丙烷化反应合成手性环丙基碳环嘌呤核苷类似物。以手性钌(II)-苯基恶唑啉配合物为催化剂,可得到含三个连续立体中心的环丙基碳环嘌呤核苷类似物,收率高达99%,ee高达99%。此外,使用该策略可以简明方式合成具有抗BLV活性的手性环丙基碳环腺苷核苷。
查看更多